Protara Therapeutics(TARA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update · On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024 · Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025 · In pediatric LMs patients, TARA-002 demonstrated encouraging results and was generally well-tolerated in the first cohort of Phase 2 STARBORN-1 trial; initial results from next cohort ex ...